Healthy start! Rubicon Research shares list at 28% premium over IPO price
Shares of the Pharmaceutical company Rubicon Research listed with a premium of 27.9% over the IPO price on Thursday. The stock opened at Rs 620 and Rs 620.10 on NSE and BSE, respectively, as compared to its issue price of Rs 485.
The Rs 1,377 crore IPO, which closed for subscription on October 13, attracted stellar demand across investor categories, being subscribed to an impressive 109 times.
The Qualified Institutional Buyers (QIBs) portion led the show with 137.09 times the bids, followed by Non-Institutional Investors (NIIs) at 102.7 times, and retail investors at 37.4 times. The strong response places Rubicon among the most heavily subscribed pharma IPOs of 2025.
Analysts attribute the excitement around Rubicon to its robust…
